Mantell Associates

Don't just listen to us - listen to what our clients and candidates have to say about working with us! "Amazing experience in the whole process. Jack was very accommodating and helped me understand the steps and he was always rooting for me!" Get in touch with Jack Lyons to discuss your next career move, or growing your current team! #testimonialtuesday #pharmarecruitment #lifesciencerecruitment

Enhertu’s market conquest is continuing apace. Already tracking at $5 billion in annual sales, the star antibody-drug conjugate from Daiichi Sankyo US and AstraZeneca has secured FDA approval to treat early breast cancer, further encroaching on Roche’s Kadcyla territory. Read more below: https://lnkd.in/eGzJYwQR #pharmanews #fda #breastcancer

The calling card of Alzheimer’s disease is a buildup of misfolded amyloid protein in the brain, but many medicines struggle to penetrate the barrier protecting the mind from outside interference. A new study suggests that crossing the blood-brain barrier might not be necessary at all to clear amyloid plaques - and that a one-time gene therapy could one day prove an effective treatment for the devastating neurodegenerative disease. Read more below: https://lnkd.in/eGr8NaTF #biotechnews #alzheimers #genetherapy

Banyan BioInnovations is debuting with more than $100 million aimed at developing independent companies for promising clinical-stage treatments, plus a partnership with global contract research organization (CRO) Icon. Read more below: https://lnkd.in/eNRaedF7 #biotechnews #cro #lifesciences

When Gilead Sciences rolled out its first sales projections for twice-yearly pre-exposure prophylaxis (PrEP) med Yeztugo (lenacapivir) at the start of this year, analysts dubbed the company’s $800 million outlook “probably” conservative and “quite doable.” Read more below: https://lnkd.in/g2bCUjFj #pharmanews #pharma #scientificnews

The U.S. FDA has cleared Harbour BioMed’s Investigational New Drug (IND) application for HBM7004, enabling the initiation of a first-in-human (FIH) Phase I clinical trial. Read more below: https://lnkd.in/esRipxg3 #pharmanews #fda #clinicaltrials

Don't just listen to us, listen to what our clients and candidates have to say about working with us! "Vincent’s energy is infectious! He was on top of the recruitment process from beginning to end and was in constant communication to ensure everything went smoothly. Highly recommend!" Get in touch with Vincent M. on +44 (0)20 3854 7700. #testimonialtuesday #recruitmentlondon #pharmarecruitment

LenioBio and Twist Bioscience are uniting to speed protein expression services’ design-build-test cycle, giving faster results to customers’ AI models. Their collaborative agreement integrates LenioBio’s cell-free protein expression platform, ALiCE, with Twist’s DNA manufacturing and automation capabilities. The two companies aim to quicken experimental results from AI models for customers and other partners. Read more below: https://lnkd.in/ejuhv8x3 #pharmanews #drugdiscovery #biosciences

MA's Q1 incentive trip to Dubrovnik! Last week our top performers travelled to Croatia for 3 days, on our quarterly all-expenses paid trip. It was a great few days full of amazing food, beautiful views, and most importantly spending time together as a team outside of the office. Following 3 back to back £1M+ months, this was perfect timing to celebrate our team's success and look ahead to the rest of 2026! Congratulation to everyone who qualified - Vincent M., Pasindu de Silva, Conor O'Shea, Abbie Mousley, Millie Bone, Ewan Rennison, Fernand Desjarlais, George Hebden Lee, Siobhan McLoughlin and Maddy Savva! We already can't wait for the Q2 trip, destination to be confirmed... #recruitmentlondon #pharmarecruitment #lifesciencerecruitment

Odyssey Therapeutics has become the latest biotech to voyage to the public markets via an upsized $304 million IPO. Read more below: https://lnkd.in/eCfR-M5r #biotechnews #autoimmune #biotech